Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 13 of 13

List	Outcome	Time frame	Description
Primary	Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response	Measured at Day 42	Microbial response was defined as follows: * A negative blood culture test at 42 days after randomization for subjects with fungemia (candidemia or fusariosis) or bacteremia. * Improvement of signs and symptoms of infectious disease (complete or partial response) at 42 days after randomization.
Secondary	Alloimmunization, Defined as the Appearance of Anti-human Leukocyte Antigen (HLA) or Antineutrophil Antibodies	Measured at Days 14 and 42
Secondary	Serious Granulocyte Transfusion Reactions, Including Febrile, Allergic, and Pulmonary Reactions (Transfusion Arm Only)	Measured within 6 hours after end of transfusion
Secondary	Graft Versus Host Disease Among Recipients of Allogeneic Stem Cell Transplantation	Measured at Day 42	Time to GVHD incidence between the two treatment groups was compared using Gray's model that takes into account death as a competing risk.
Secondary	Overall Incidence of Adverse Effects	Measured through Day 42
Secondary	Fever Resolution	Measured through Day 42	Fever resolution between the two treatment groups was compared using Gray's model that takes into account death as a competing risk.
Secondary	Time to Negative Test for Fungal Antigenemia (e.g., Galactomannan Antigenemia Among Participants With Invasive Aspergillosis)	Measured at Days 7, 14, and 42
Secondary	Time to Negative Blood Culture for Participants With Positive Blood Culture at Baseline	Measured through Day 42
Secondary	Long-term Survival	Measured at Month 3
Secondary	Serious Adverse Events in Granulocyte Donors	Measured at Week 1 after G-CSF administration
Secondary	Donor Availability (Proportion of Scheduled Granulocyte Transfusion Days on Which Granulocytes Were Available)	Measured through study completion
Secondary	Evaluation of Granulocyte Yield	Measured immediately after each granulocyte donation
Secondary	Discontinuation of Granulocyte Transfusions Due to Toxicity or Intolerance	Measured through Day 42

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00627393/registered

API reference For AI assistants